Compare Adaptive Biotechnologies Corp (ADPT) vs United Microelectronics Corp (UMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs United Microelectronics Corp — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while United Microelectronics Corp trades at $24.8 (market cap $60.80B). The key difference: United Microelectronics Corp is far larger — about 18.3× Adaptive Biotechnologies Corp's market cap, and United Microelectronics Corp pays a 1.73% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | UMC | |
|---|---|---|
Market Cap | $3.33B | $60.80B |
Sector | Health | Technology |
52-Week High | $22.37 | $28.02 |
52-Week Low | $10.24 | $6.58 |
Enterprise Value | $3.19B | $58.38B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
UMC trades at $23.83, down 2.89% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $237.55 billion in 2025, though net income margin compressed to 16.99%. The company maintains strong cash flow from operations and announced a $0.41 dividend for H2-26, reflecting financial stability amid competitive semiconductor market dynamics.
Outlook remains supported by specialty chip demand and 14nm eHV platform innovation, but valuation multiples like P/E of 41.94 suggest premium pricing. Risks include margin pressure and industry cyclicality, while analyst consensus leans hold with 53.33% neutral ratings, indicating cautious optimism for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
